Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients

被引:36
|
作者
Lindegaard, B
Keller, P
Bruunsgaard, H
Gerstoft, J
Pedersen, BK
机构
[1] Univ Copenhagen, Rigshosp, Copenhagen Muscle Res Ctr, DK-1168 Copenhagen, Denmark
[2] Univ Copenhagen, Rigshosp, Dept Infect Dis, DK-1168 Copenhagen, Denmark
来源
CLINICAL AND EXPERIMENTAL IMMUNOLOGY | 2004年 / 135卷 / 02期
关键词
HIV; lipodystrophy; insulin resistance; adiponectin; cytokines;
D O I
10.1111/j.1365-2249.2004.02367.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This study tested the hypothesis that in patients with HIV-associated lipodystrophy, adiponectin levels were related to insulin resistance, TNF-alpha and IL-6 and treatment with nucleoside analaogues. HIV seropositive men undergoing highly active antiretroviral treatment were enrolled into three predetermined clinical groups: lipodystrophy with central fat accumulation (n = 12); lipodystrophy without central fat accumulation (n = 15); no lipodystrophy (n = 15). HIV-negative healthy men served as controls (n = 12). Both lipodystrophic groups had a low percentage of limb fat compared to the two control groups. Patients with lipodystrophy with fat accumulation had increased truncal fat compared with controls. Levels of adiponectin did not correlate with either TNF-alpha or IL-6. Low levels of adiponectin were found in both lipodystrophic groups and were associated with current or previous treatment with stavudine. Furthermore, the adiponectin level correlated with the percentage of limb fat. Patients with lipodystrophy with fat accumulation were more insulin resistant, measured by HOMA-IR, compared with controls. However, HOMA-IR did no correlate to adiponectin or other cytokines. In conclusion, the finding of no difference between the two lipodystrophic groups with regard to adiponectin, indicates that low levels of adiponectin reflects fat atrophy, whereas the insulin resistance was best explained by increased truncal fat mass.
引用
收藏
页码:273 / 279
页数:7
相关论文
共 50 条
  • [21] Emergence of zidovudine resistance in HIV-Infected patients receiving stavudine
    de Mendoza, C
    Soriano, V
    Briones, C
    Gallego, O
    Barreiro, P
    Alvarez, A
    González-Lahoz, J
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 23 (03) : 279 - 281
  • [22] Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon
    Cournil, Amandine
    Coudray, Mathilde
    Kouanfack, Charles
    Essomba, Claudine Ntsama
    Tonfack, Clement Auguste Djouatsa
    Biwole-Sida, Magloire
    Delaporte, Eric
    Bork, Kirsten
    Laurent, Christian
    [J]. ANTIVIRAL THERAPY, 2010, 15 (07) : 1039 - 1043
  • [23] Increased homocysteine plasma level is associated with shortened prothrombin time in HIV-infected patients
    Roca, Bernardino
    Roca, Manuel
    Girones, Guillermo
    [J]. HIV CLINICAL TRIALS, 2016, 17 (05): : 218 - 223
  • [25] Effects of Switching from Stavudine to Raltegravir on Subcutaneous Adipose Tissue in HIV-Infected Patients with HIV/HAART-Associated Lipodystrophy Syndrome (HALS). A Clinical and Molecular Study
    Domingo, Pere
    del Mar Gutierrez, Maria
    Miguel Gallego-Escuredo, Jose
    Torres, Ferran
    Maria Mateo, Gracia
    Villarroya, Joan
    de los Santos, Ignacio
    Carles Domingo, Joan
    Villarroya, Francesc
    Del Rio, Luis
    Estrada, Vicente
    Giralt, Marta
    [J]. PLOS ONE, 2014, 9 (02):
  • [26] Severity of the toxicity associated with combinations that include didanosine plus stavudine in HIV-infected experienced patients
    Hernandez, Beatriz
    Moreno, Santiago
    Perez-Elias, Maria J.
    Casado, Jose L.
    Dronda, Fernando
    Moreno, Ana
    Antela, Antonio
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (05) : 556 - 559
  • [27] Low Plasma Lipids Are Associated with Relapsing and Lethal Visceral Leishmaniasis in HIV-Infected Patients
    Silva, Renata V. S.
    Uliana, Silvia R. B.
    Yasunaka, Jenicer K. U. Y.
    Veloso, Claudio S.
    Sousa, Emille
    Ferreira, Maria M. L.
    Carvalho, Vivianne S.
    Ferreira, Gabriel R.
    Costa, Dorcas L.
    Costa, Carlos H. N.
    [J]. PATHOGENS, 2024, 13 (06):
  • [28] Metabolic syndrome and cardiovascular risk in HIV-infected patients with lipodystrophy
    Falasca, K.
    Ucciferri, C.
    Manzoli, L.
    Mancino, P.
    Pizzigallo, E.
    Conti, P.
    Vecchiet, J.
    [J]. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2007, 20 (03) : 519 - 527
  • [29] Regional body fat distribution in HIV-infected patients with lipodystrophy
    Dinges, WL
    Chen, DL
    Snell, PG
    Weatherall, PT
    Peterson, DM
    Garg, A
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2005, 53 (01) : 15 - 25
  • [30] Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors
    Temple, ME
    Koranyi, KI
    Nahata, MC
    [J]. ANNALS OF PHARMACOTHERAPY, 2003, 37 (09) : 1214 - 1218